Cath Lab

The cardiac catheterization laboratory is used for diagnostic angiograms and percutaneous coronary interventions (PCI). Cath labs have also seen expanding use in recent years for transcatheter structural heart procedures. Some hospitals also share these labs with other subspecialties for catheter-based procedures in electrophysiology (EP), interventional radiology, peripheral artery disease (PAD), carotid and neuro interventional procedures and vascular surgery.

Ajay J. Kirtane, MD, director of the cardiac catheterization laboratories and professor of medicine at NewYork-Presbyterian/Columbia University Irving Medical Center, explains the current trial data on catheter renal denervation to treat drug-resistant hypertension at AHA 2022.

Where renal denervation stands for the treatment of drug-resistant hypertension

Ajay Kirtane, MD, director of the cardiac catheterization laboratories at NewYork-Presbyterian/Columbia University Irving Medical Center, explained the most recent clinical trial data on this topic. 

Samir Kapadia, MD, chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at Cleveland Clinic, explains why he believes the results of the late-breaking PROTECTED TAVR testing the use of a TAVR cerebral protection device were positive, although it did not meet its primary endpoint.

VIDEO: Exploring the use of cerebral protection devices during TAVR

Samir Kapadia, MD, chair of the department of cardiovascular medicine at Cleveland Clinic, shared his perspective on the use of cerebral protection devices during TAVR procedures. 

Thumbnail

Coronary IVL now recommended at all cath labs, even those without surgical backup

The latest SCAI guidance on the safety of PCI procedures included a key change that could expand coronary IVL utilization throughout the United States. 

Interventional cardiologists can safely perform PCI without on-site surgical backup

The finding comes from a new expert consensus statement published by the Society for Cardiovascular Angiography and Interventions. Several industry societies, including the ACC and AHA, have endorsed the document. 

FDA issues new recall for circulatory support system after software update

The device was first recalled in 2022, but a new software update has now been released that addresses the issue. The FDA wanted a new recall to be issued to ensure all customers went through with the update.

Thumbnail

EHR intervention targets acute kidney injuries after PCI

Contrast-associated acute kidney injury is a significant problem in cardiology, especially among patients undergoing percutaneous coronary intervention. Can EHR-generated alerts make an impact?

 The Neovasc Reducer System is designed to treat the symptoms of refractory angina by altering a patient's blood flow.

Shockwave Medical to acquire medical device company for $100M

Shockwave Medical's decision to acquire Neovasc is based largely on the potential of the Neovasc Reducer System, a solution designed to treat the symptoms of refractory angina by altering a patient's blood flow.

Abbott has gained U.S. Food and Drug Administration (FDA) approval for its Navitor transcatheter aortic valve replacement (TAVR) system, the company’s new self-expanding valve for high-risk patients with severe symptomatic aortic stenosis.

Abbott receives FDA approval for new self-expanding TAVR system

The device, which gained CE mark approval in Europe in May 2021, features a new-look fabric cuff designed to keep the risk of paravalvular leak (PVL) at a minimum.